Nonsteroidal FXR agonist cilofexor (GS-9674) (NCT02854605) [295], nonbile acid FXR agonist tropifexor (LJN452) (NCT02855164) [297], and nidufexor (LMB763) (NCT02913105) [298] are undergoing phase 2 clinical trial in NASH patients. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.